By Bhanvi Satija LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated ...
Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of ...
COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver ...
The Trump administration has also pushed back against Covid vaccine recommendations, and the FDA toughened its requirements ...
Morning Overview on MSN
Pfizer and BioNTech pause US COVID vaccine trial after slow enrollment
Pfizer and BioNTech have paused a large U.S. clinical trial designed to test their updated COVID-19 vaccine in healthy adults ...
Pfizer PFE and partner BioNTech BNTX announced that a phase III study evaluating an mRNA-based combination vaccine candidate against influenza and COVID-19 missed one of its two primary immunogenicity ...
A pivotal clinical trial has been terminated prematurely, marking a significant setback for Pfizer and BioNTech. Their large U.S. study for the COVID-19 vaccine ...
Biontech Se Sponsored Adr ((BNTX)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...
BioNTech SE is navigating a complex transition, pouring billions into oncology while contending with clinical setbacks and shifting trade policies. The German biotech's ambitious pivot from a pandemic ...
The trial is tied to a post-marketing commitment that FDA Commissioner Martin Makary put in place last year for all approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results